• Vaccine Ontology ID: VO_0004031
• Type: DNA vaccine
• Status: Research
• Antigen: The hly gene of L. monocytogenes
• Hly gene engineering:
  • Type: DNA vaccine construction
  • Detailed Gene Information: Click Here.
• Vector: pCR3.1 plasmid vector (Invitrogen)
• Immunization Route: Intramuscular injection (i.m.)

• Vaccine Ontology ID: VO_0004032
• Type: Subunit vaccine
• Status: Research
• Antigen: p60 protein
• iap gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • VO ID: VO_0000366
• Immunization Route: Intraperitoneal injection (i.p.)

• Vaccine Ontology ID: VO_0002776
• Type: Live, attenuated vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Mouse
• actA gene engineering:
  • Type: Gene mutation
  • Description: This actA mutant is from Listeria monocytogenes (Darji et al., 2003).
  • Detailed Gene Information: Click Here.
• Immunization Route: Intravenous injection (i.v.)

• Type: Live, attenuated vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Mouse
• actA gene engineering:
  • Type: Gene mutation
  • Description: This actA/plcB mutant is from Listeria monocytogenes (Darji et al., 2003).
  • Detailed Gene Information: Click Here.
• plcB gene engineering:
  • Type: Gene mutation
  • Description: This actA/plcB mutant is from Listeria monocytogenes (Darji et al., 2003).
  • Detailed Gene Information: Click Here.
• Immunization Route: Intravenous injection (i.v.)

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: For immunization with the plasmid constructs, 6-to 8-wk-old mice received the first of a series of three i.m. immunizations (via the tibialis anterior muscles) at 3- to 4-wk intervals with ~100–125 µg of plasmid DNA in 50 µl of normal saline. Normal control mice received either no immunization or were immunized with either 0.2 ml of PBS (i.v.) or 50 µl of saline (i.m.) (Cornell et al., 1999).
• Challenge Protocol: Briefly, groups of normal or immunized BALB/c mice received an i.v. injection with ~2 LD50 (~20,000 CFU) of L. monocytogenes in 0.2 ml of PBS, at 3–4 wk following the final immunization with plasmid DNA. Control groups consisted of normal (nonimmunized) mice and mice previously immunized (4–12 wk earlier) with a sublethal injection of viable L. monocytogenes (Cornell et al., 1999).
• Efficacy: DNA immunization of mice provides protection against challenge with viable L. monocytogenes (Cornell et al., 1999).

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: BALB/c mice (two mice/group) were immunized i.p. with 100 μl liposomes containing approximately 3 μg of p60 antigen shown (Grenningloh et al., 2008).
• Challenge Protocol: BALB/c mice were immunized with encapsulated p60 and challenged intravenously on day 9 after immunization with 5 × 10^3 (1 × LD50) L. monocytogenes (Grenningloh et al., 2008).
• Efficacy: Mice immunized with p60 encapsulated in liposomes launched a strong CTL response and were protected against a subsequent challenge with L. monocytogenes (Grenningloh et al., 2008).

Mouse Response

• Persistence: An actA mutant is attenuated in mice (Darji et al., 2003).
• Efficacy: An actA mutant induces significant protection in mice from challenge with wild type L. monocytogenes (Darji et al., 2003).

Mouse Response

• Persistence: An actA/plcB mutant is attenuated in mice (Darji et al., 2003).
• Efficacy: An actA/plcB mutant induces significant protection in mice from challenge with wild type L. monocytogenes (Darji et al., 2003).
• Host Ifng (Interferon gamma) response
  • Description: The ΔactAΔplcB mutant is able to induce sufficient IFN-γ in mice to prevent a Th1 to Th2 switch and retains its ability to induce a strong CD8+-mediated T cell response, even though the amount of IFN-gamma produced is less than that produced after infection with the wild type strain (Darji et al., 2003).
  • Detailed Gene Information: Click Here.